The Quality Improvement Plan describes the approach taken across the NATCAN cancer audits to develop improvement goals and performance indicators, aiming for these to be measurable, actionable and improvable.
The NPCA Quality Improvement goals, developed following a thorough scoping exercise in 2023 and in consultation with stakeholders in the Clinical Reference Group (CRG) are as follows:
• Maintaining use of active surveillance to treat men with low-risk prostate cancer, thus reducing potential over-treatment
• Increasing use of multimodality therapy for men with high-risk or locally advance prostate cancer, thus reducing potential under-treatment
• Improving safety and reducing toxicity of prostate cancer therapy
• Reducing variation in prostate cancer management among NHS providers
• Improving experience of care among men with prostate cancer
The NPCA reports on seven performance indicators to monitor progress against these five improvement goals and how they map to clinical guidelines and standards. A range of improvement methods and activities to help deliver the Quality Improvement Plan are also described.
Quality Improvement goals and performance indicators from all NATCAN audits can be found below.
NATCAN Q1 Goals